SLSN SOLESENCE, INC.
Perfumes, Cosmetics & Other Toilet Preparations · Nasdaq · SEC CIK 883107 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.0%
TTM net income YoY364.7%
TTM EPS YoY1,152,921,504,606,847,232.0%
Revenue 3-yr CAGR17.5%
Net income 3-yr CAGR—
Margins
Gross margin31.7%
Operating margin6.0%
Net margin4.5%
FCF margin—
EBITDA margin8.0%
Returns
ROE18.2%
ROA5.8%
ROIC (approx.)25.8%
Asset turnover1.29x
Leverage & solvency
Liabilities / assets62.3%
Debt / equity0.00x
Current ratio1.73x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.72x
Accruals ratio-15.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $20.16M | $15.33M | $12.96M | $12.48M | $14.60M | $20.36M | $14.62M | $12.57M |
| Cost of revenue | $12.23M | $10.68M | $9.79M | $8.94M | $11.12M | $13.83M | $11.09M | $11.19M |
| Gross profit | $7.93M | $4.65M | $3.17M | $3.54M | $3.47M | $6.53M | $3.53M | $1.38M |
| R&D expense | $1.08M | $947,000 | $1.04M | $1.03M | $1.08M | $955,000 | $1.02M | $1.09M |
| SG&A expense | $2.81M | $3.68M | $2.80M | $2.21M | $3.07M | $3.01M | $2.11M | $1.90M |
| Operating income | $4.04M | $23,000 | -$674,000 | $296,000 | -$677,000 | $2.56M | $407,000 | -$1.61M |
| Interest expense | — | — | — | — | — | — | $176,000 | $108,000 |
| Pretax income | $3.89M | -$256,000 | -$936,000 | -$44,000 | -$1.02M | $3.71M | $231,000 | -$1.72M |
| Income tax | $219,000 | — | — | -$317,000 | $0 | $390,000 | — | — |
| Net income | $3.67M | -$256,000 | -$936,000 | $273,000 | -$1.02M | $3.32M | $231,000 | -$1.94M |
| EBITDA | $4.35M | $346,000 | -$361,000 | $517,000 | -$452,000 | $2.79M | $633,000 | -$1.38M |
| EPS (basic) | 0.05 | 0.00 | -0.01 | — | -0.01 | 0.05 | 0.00 | — |
| EPS (diluted) | 0.05 | 0.00 | -0.01 | — | -0.01 | 0.05 | 0.00 | — |
| Weighted avg. shares (diluted) | 71.48M | 70.64M | 70.63M | — | 70.50M | 72.58M | 72.63M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.27M | $1.05M | $573,000 | $1.29M | $429,000 | $429,000 | $1.82M | $1.41M |
| Receivables | $8.36M | $9.35M | $6.38M | $6.84M | $9.71M | $11.05M | $9.09M | $4.87M |
| Inventory | $11.59M | $12.80M | $13.76M | $14.88M | $15.13M | $19.83M | $21.91M | $15.62M |
| Current assets | $23.26M | $25.11M | $22.61M | $25.14M | $29.05M | $38.77M | $35.90M | $24.70M |
| PP&E, net | $15.01M | $14.79M | $14.75M | $14.33M | $13.94M | $13.56M | $13.11M | $12.73M |
| Total assets | $44.44M | $46.28M | $43.99M | $46.42M | $50.24M | $59.96M | $57.02M | $45.35M |
| Current liabilities | $13.45M | $26.01M | $12.69M | $13.93M | $17.86M | $22.54M | $32.88M | $25.77M |
| Total liabilities | $27.69M | $33.28M | $30.83M | $32.42M | $36.76M | $45.61M | $46.36M | $35.06M |
| Shareholders' equity | $16.75M | $13.00M | $13.16M | $14.00M | $13.48M | $14.34M | $10.66M | $10.29M |
| Shares outstanding | 70.65M | 70.65M | 70.63M | 70.61M | 70.54M | 70.48M | 70.10M | 70.10M |
| Cash flow statement | ||||||||
| Operating cash flow | $6.72M | $191,000 | $1.52M | $1.82M | -$2.51M | -$654,000 | -$7.22M | $2.19M |
| Capital expenditure | — | — | — | — | — | — | — | $2.59M |
| Free cash flow | — | — | — | — | — | — | — | -$404,000 |
| Investing cash flow | -$538,000 | -$469,000 | -$528,000 | -$450,000 | -$418,000 | -$1.41M | $133,000 | -$2.59M |
| Financing cash flow | -$5.96M | $751,000 | -$1.70M | -$510,000 | -$750,000 | $4.35M | $7.50M | -$1.11M |
| Depreciation & amortization | $313,000 | $323,000 | $313,000 | $221,000 | $225,000 | $225,000 | $226,000 | $228,000 |
| Stock-based compensation | $83,000 | $79,000 | $82,000 | $206,000 | $122,000 | $120,000 | $127,000 | $248,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.